A retrospective study by Wang et al. suggests that a high Tumor Mutation Burden (TMB) indicates a better prognosis in colorectal cancer (CRC) patients with KRAS mutations, thereby confirming the clinical utility of TMB in prognostic assessments [221]. The gene discussed is KRAS; the disease is colorectal carcinoma.